#CELU Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
https://www.stocktitan.net/news/CELU/celularity-highlights-anticipated-quarter-one-2027-opening-of-5g9k3z663acc.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELU/celularity-highlights-anticipated-quarter-one-2027-opening-of-5g9k3z663acc.html?utm_source=stocktitan-bluesky&utm_medium=social
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Celularity (CELU) highlighted progress at Fontaine Vitale, a regenerative medicine and wellness center expected to open in the first quarter of 2027.Genting Berhad and its Indonesian partners are developing the center in Bali’s Sanur Special Economic Zone, with collaboration and input from Celularity. The facility is expected to offer placenta-derived allogeneic stem cell therapy, which uses donor cells, using Celularity’s technology and products manufactured in New Jersey. Celularity expects to supply its placenta-derived products, subject to final commercial arrangements, applicable regulatory authorizations, treatment protocols and market conditions.
www.stocktitan.net
September 30, 2026 at 3:58 PM
#CELU Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
https://www.stocktitan.net/news/CELU/celularity-highlights-anticipated-quarter-one-2027-opening-of-5g9k3z663acc.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELU/celularity-highlights-anticipated-quarter-one-2027-opening-of-5g9k3z663acc.html?utm_source=stocktitan-bluesky&utm_medium=social
Celularity Inc (0001752828) (Filer) (cik: 0001752828) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1752828/000149315226044917/0001493152-26-044917-index.htm
September 29, 2026 at 9:40 PM
Celularity Inc (0001752828) (Filer) (cik: 0001752828) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1752828/000149315226044917/0001493152-26-044917-index.htm
Celularity Inc (0001752828) (Filer) (cik: 0001752828) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1752828/000149315226044421/0001493152-26-044421-index.htm
September 28, 2026 at 10:31 AM
Celularity Inc (0001752828) (Filer) (cik: 0001752828) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1752828/000149315226044421/0001493152-26-044421-index.htm
Celularity & 2 other perinatal biologics firms get FDA warnings. Let's dig into these and discuss what they tell us about the FDA in the RFK Jr. era and with state stem cell laws saying FDA approval isn't needed ipscell.com/2025/12/celu... #stemcells #stemcell
Celularity & 2 other perinatal biologics firms get FDA warnings - The Niche
Three recent FDA warning letters, including one issued to publicly-traded Celularity, paint a helpful picture of where FDA oversight stands. They illustrate how the FDA’s classification of placental/a...
ipscell.com
December 16, 2025 at 7:04 PM
Celularity & 2 other perinatal biologics firms get FDA warnings. Let's dig into these and discuss what they tell us about the FDA in the RFK Jr. era and with state stem cell laws saying FDA approval isn't needed ipscell.com/2025/12/celu... #stemcells #stemcell
ICYMI: Pivot of Nasdaq-traded biotech Celularity that will market non-FDA-approved placental cells in FL highlights tensions & risks from new tem cell laws across red states #stemcells ipscell.com/2025/08/pivo... #stemcell $CELU
Pivot of Nasdaq-traded Celularity highlights tensions & risks from Florida stem cell law - The Niche
Professor gives perspectives on Bob Hariri Fox News interview: Celularity, Fountain Life, and new Florida Stem Cell Law.
ipscell.com
August 8, 2025 at 7:58 PM
ICYMI: Pivot of Nasdaq-traded biotech Celularity that will market non-FDA-approved placental cells in FL highlights tensions & risks from new tem cell laws across red states #stemcells ipscell.com/2025/08/pivo... #stemcell $CELU
🚨 $CELUW
(d) Exhibits 99.1 Press release issued by Celularity Inc. on September 29, 2026. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its ...
(d) Exhibits 99.1 Press release issued by Celularity Inc. on September 29, 2026. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its ...
SEC Filing: CELUW
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 9:26 PM
🚨 $CELUW
(d) Exhibits 99.1 Press release issued by Celularity Inc. on September 29, 2026. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its ...
(d) Exhibits 99.1 Press release issued by Celularity Inc. on September 29, 2026. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its ...
🚨 $CELUW
Securities Purchase Agreement On September 23, 2026, Celularity Inc. entered into a Securities Purchase Agreement with the purchasers party thereto , pursuant to which the Company may issue and sell up to an aggregate principal amount of $25.0 million of senior secured convertible promis...
Securities Purchase Agreement On September 23, 2026, Celularity Inc. entered into a Securities Purchase Agreement with the purchasers party thereto , pursuant to which the Company may issue and sell up to an aggregate principal amount of $25.0 million of senior secured convertible promis...
SEC Filing: CELUW
Click to view the official SEC document.
www.sec.gov
September 28, 2026 at 10:14 AM
🚨 $CELUW
Securities Purchase Agreement On September 23, 2026, Celularity Inc. entered into a Securities Purchase Agreement with the purchasers party thereto , pursuant to which the Company may issue and sell up to an aggregate principal amount of $25.0 million of senior secured convertible promis...
Securities Purchase Agreement On September 23, 2026, Celularity Inc. entered into a Securities Purchase Agreement with the purchasers party thereto , pursuant to which the Company may issue and sell up to an aggregate principal amount of $25.0 million of senior secured convertible promis...
Biotech firm #Celularity announced a new manufacturing collaboration that has the potential to bring $300 million in business and hundreds of jobs to Morris County. https://njbiz.com/celularity-florham-park-manufacturing-jobs/
Celularity deal could bring $300M, 200 jobs to NJ
A new Celularity manufacturing deal could bring $300 million in business and more than 200 high-tech jobs to Florham Park.
njbiz.com
August 28, 2026 at 12:57 PM
Biotech firm #Celularity announced a new manufacturing collaboration that has the potential to bring $300 million in business and hundreds of jobs to Morris County. https://njbiz.com/celularity-florham-park-manufacturing-jobs/
#CELU #CELUW Celularity Inc. Announces Receipt of Nasdaq Notification
#news #StockMarket #investing
https://www.stocktitan.net/news/CELU/celularity-inc-announces-receipt-of-nasdaq-02do4fcxzkrk.html
#news #StockMarket #investing
https://www.stocktitan.net/news/CELU/celularity-inc-announces-receipt-of-nasdaq-02do4fcxzkrk.html
Celularity Faces Nasdaq Non-Compliance Notice Over Delayed Q3 Filing | CELU Stock News
Celularity must submit compliance plan by Jan 2025 following Nasdaq warning over Q3 filing delay. Company cites reporting backlog but expects to file shortly.
www.stocktitan.net
November 27, 2024 at 10:00 PM
#CELU #CELUW Celularity Inc. Announces Receipt of Nasdaq Notification
#news #StockMarket #investing
https://www.stocktitan.net/news/CELU/celularity-inc-announces-receipt-of-nasdaq-02do4fcxzkrk.html
#news #StockMarket #investing
https://www.stocktitan.net/news/CELU/celularity-inc-announces-receipt-of-nasdaq-02do4fcxzkrk.html
#CELU Celularity Provides Update Regarding Nasdaq Listing Compliance
https://www.stocktitan.net/news/CELU/celularity-provides-update-regarding-nasdaq-listing-osepyvf7a796.html
https://www.stocktitan.net/news/CELU/celularity-provides-update-regarding-nasdaq-listing-osepyvf7a796.html
Celularity Provides Update Regarding Nasdaq Listing Compliance
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
August 25, 2026 at 11:59 PM
#CELU Celularity Provides Update Regarding Nasdaq Listing Compliance
https://www.stocktitan.net/news/CELU/celularity-provides-update-regarding-nasdaq-listing-osepyvf7a796.html
https://www.stocktitan.net/news/CELU/celularity-provides-update-regarding-nasdaq-listing-osepyvf7a796.html
#CELU Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
https://www.stocktitan.net/news/CELU/celularity-and-muse-cell-innovations-announce-u-s-manufacturing-vhf5tu61ycx7.html
https://www.stocktitan.net/news/CELU/celularity-and-muse-cell-innovations-announce-u-s-manufacturing-vhf5tu61ycx7.html
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
August 27, 2026 at 1:00 PM
#CELU Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
https://www.stocktitan.net/news/CELU/celularity-and-muse-cell-innovations-announce-u-s-manufacturing-vhf5tu61ycx7.html
https://www.stocktitan.net/news/CELU/celularity-and-muse-cell-innovations-announce-u-s-manufacturing-vhf5tu61ycx7.html
Celularity also retired nearly $13.0 million of debt, strengthening its balance sheet, while remaining eligible for up to $20.0 million in milestone payments and royalties. The deal enables Celularity to f...
🚀 Free alerts → https://gunpowderalerts.com/yisf4z
#StockMarket #RegulatoryCompliance #8K
🚀 Free alerts → https://gunpowderalerts.com/yisf4z
#StockMarket #RegulatoryCompliance #8K
April 21, 2026 at 2:01 PM
Celularity also retired nearly $13.0 million of debt, strengthening its balance sheet, while remaining eligible for up to $20.0 million in milestone payments and royalties. The deal enables Celularity to f...
🚀 Free alerts → https://gunpowderalerts.com/yisf4z
#StockMarket #RegulatoryCompliance #8K
🚀 Free alerts → https://gunpowderalerts.com/yisf4z
#StockMarket #RegulatoryCompliance #8K
Breaking News: ( NASDAQ: #CELU ) Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
#StockMarket #News
#StockMarket #News
October 23, 2024 at 3:15 PM
Breaking News: ( NASDAQ: #CELU ) Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
#StockMarket #News
#StockMarket #News
BREAKING NEWS: ( NASDAQ: #CELU ) Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
#StockMarket #News
#StockMarket #News
November 7, 2024 at 3:20 PM
FDA has issued a warning letter to Celularity. According to the letter, sent to company founder and CEO Robert Hariri, Celularity's Interfyl, a deceullarized human placental connective tissue matrix product, is an unapproved new drug & unlicensed biological product. www.fda.gov/inspections-...
Celularity, Inc - 681480 - 12/01/2025
Unapproved New Drug/Unlicensed Biological Product/Biologics License Application (BLA)
www.fda.gov
December 10, 2025 at 5:49 PM
FDA has issued a warning letter to Celularity. According to the letter, sent to company founder and CEO Robert Hariri, Celularity's Interfyl, a deceullarized human placental connective tissue matrix product, is an unapproved new drug & unlicensed biological product. www.fda.gov/inspections-...
ICYMI: 3 recent interesting FDA warning letters on placental/amniotic products suggest some lessons on where the agency is at now and future trends ipscell.com/2025/12/celu... #stemcells #stemcell
Celularity & 2 other perinatal biologics firms get FDA warnings - The Niche
Three recent FDA warning letters, including one issued to publicly-traded Celularity, paint a helpful picture of where FDA oversight stands. They illustrate how the FDA’s classification of placental/a...
ipscell.com
December 17, 2025 at 5:02 PM
ICYMI: 3 recent interesting FDA warning letters on placental/amniotic products suggest some lessons on where the agency is at now and future trends ipscell.com/2025/12/celu... #stemcells #stemcell
🚨 $CELUW
On September 11, 2026, Celularity Inc. received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that Celularity has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market...
On September 11, 2026, Celularity Inc. received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that Celularity has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market...
SEC Filing: CELUW
Click to view the official SEC document.
www.sec.gov
September 14, 2026 at 1:01 PM
🚨 $CELUW
On September 11, 2026, Celularity Inc. received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that Celularity has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market...
On September 11, 2026, Celularity Inc. received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that Celularity has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market...
$CELUW — Other Company Update
Celularity Inc. regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements (Rules 5550(a)(2) and 5550(b)(2)), and both matters are closed.
🧵 continued ↓
Celularity Inc. regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements (Rules 5550(a)(2) and 5550(b)(2)), and both matters are closed.
🧵 continued ↓
September 14, 2026 at 6:17 PM
$CELUW — Other Company Update
Celularity Inc. regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements (Rules 5550(a)(2) and 5550(b)(2)), and both matters are closed.
🧵 continued ↓
Celularity Inc. regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements (Rules 5550(a)(2) and 5550(b)(2)), and both matters are closed.
🧵 continued ↓
Deal with Singapore’s MuseCell Innovations could bring $300 million in business and 200 jobs to Celularity’s cell platform.
Link as first comment.
#longevity #geroscience #musecell #celularity #cellplatform
Link as first comment.
#longevity #geroscience #musecell #celularity #cellplatform
September 8, 2026 at 10:19 AM
Deal with Singapore’s MuseCell Innovations could bring $300 million in business and 200 jobs to Celularity’s cell platform.
Link as first comment.
#longevity #geroscience #musecell #celularity #cellplatform
Link as first comment.
#longevity #geroscience #musecell #celularity #cellplatform
Celularity Signs U.S. Manufacturing Deal With MuseCell Innovations: Celularity and MuseCell Innovations (MCI) announced a U.S. manufacturing collaboration to produce Dezawa MuseCells and derived products at Celularity's New Jersey facility. MCI projects that if the… #MarketUpdates Follow Us for more
Celularity Signs U.S. Manufacturing Deal With MuseCell Innovations
Celularity and MuseCell Innovations (MCI) announced a U.S. manufacturing collaboration to produce Dezawa MuseCells and derived products at Celularity's New Jersey facility. MCI projects that if the relationship expands beyond the initial project, it could generate more than $300 million in aggregate purchases from Celularity over five years, though this remains a projection, not a signed commitment.
quantli.com
August 27, 2026 at 10:23 PM
Celularity Signs U.S. Manufacturing Deal With MuseCell Innovations: Celularity and MuseCell Innovations (MCI) announced a U.S. manufacturing collaboration to produce Dezawa MuseCells and derived products at Celularity's New Jersey facility. MCI projects that if the… #MarketUpdates Follow Us for more
🚨 Major biotech partnership! Celularity (#$CELU) and MuseCell Innovations announce a U.S. manufacturing collaboration for the Dezawa MuseCell Platform at their Florham Park, NJ facility. With #$CELU surging over 130% on massive volume ahead of earnings, momentum is electric. Stay tuned! 🧬🚀 @Celularity
August 27, 2026 at 6:33 PM
🚨 Major biotech partnership! Celularity (#$CELU) and MuseCell Innovations announce a U.S. manufacturing collaboration for the Dezawa MuseCell Platform at their Florham Park, NJ facility. With #$CELU surging over 130% on massive volume ahead of earnings, momentum is electric. Stay tuned! 🧬🚀 @Celularity